A Phase I/II Open-Label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics and Anti-Tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation

Brief description of study

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation

Clinical Study Identifier: s22-01077

Principal Investigator: Elaine Shum.

Other Investigators: Jessica Wang, James Newman, Carol M Lee, Salman Rafi Punekar, Joshua K Sabari, Marissa Rybstein, David Mendoza, Melissa L Martinez, Vamsidhar Velcheti, Jeffrey G Schneider, Avital Benson, Sally Lau, Natalia Cherkassky, Jonathan B Kahn.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies